Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Post by bitcoinruson Apr 03, 2018 2:47pm

175 Views

Post# 27822850

Huge new short position $10 million

Historical Short Volume Data for ATE.V

2018 | 2017 | 2016 | 2015

Date	Short Sale Trades	% Total Trades	Short Traded Volume	% Total Traded Volume	Short Traded Value	% Total Traded Value
Jan 1 2018	16	3.912	69,600	2.412	$9,901	2.420
Jan 16 2018	136	8.252	564,500	6.824	$109,795	7.111
Feb 1 2018	230	11.512	779,175	7.377	$176,846	7.859
Feb 16 2018	153	9.557	743,330	8.387	$166,847	8.457
Mar 1 2018	483	12.704	3,538,704	15.771	$1,038,928	15.955
Mar 16 2018	2,047	19.736	13,218,278	22.275	$4,827,174	23.146
Apr 2 2018	4,087	20.719	20,270,049	21.420	$10,741,522	21.902